Study on Long-term Outcomes of Alemtuzumab in RRMS Patients

In a study of 81 RRMS patients with an average follow-up of 65 months, alemtuzumab treatment resulted in a low mean annual relapse rate of 0.069. Approximately 80.7% of patients maintained NEDA-3 status (no evidence of disease activity) from years 2 to 7, with significant findings noted in those treated following natalizumab discontinuation.

Tags: #MSResearch
Most relevant to: —
Source: Read original source (PMID 42868842)

This plain-English summary was written by AI from a published abstract and may contain errors. It is not medical advice. Read the original study and talk to your MS team before making decisions about treatment.

Human efficacy: Not yet assessed
Mechanism: Not yet assessed
Evidence strength: Not yet assessed
Outcome: Not yet assessed

Why it matters

These findings suggest that alemtuzumab could provide sustained disease control and improve patient outcomes in RRMS, especially after prior treatment with natalizumab. However, they are based on a retrospective design and cannot establish causation.

What this does not prove

The study's observational nature and single-center design limit the generalizability of the results. Additionally, the long-term effects of alemtuzumab after natalizumab exposure require further investigation.

Next milestone

No next milestone was established from the available source.

Study facts

Study design: Observational
Participants / samples: 81 · basis not reported
Randomised: Not reported
Controlled: Not reported
Primary endpoint met: Yes
Relevant MS type: RRMS
Publication date: 2026-10-08
Evidence reviewed: Abstract only
Regulatory approval: Not reported
Research areas: Not classified

Original sources

Primary evidenceLong-term outcomes of alemtuzumab in relapsing-remitting multiple sclerosis: a real-world cohort with particular focus on treatment sequencing after natalizumab. ↗DOI: 10.1016/j.jns.2026.126210

Supporting passages (9)

study designWe conducted a retrospective, longitudinal, single-centre cohort study including RRMS patients treated with ALEM.

subjectsRESULTS: Eighty-one patients were included, with a mean follow-up after alemtuzumab of 65 months.

sample sizeRESULTS: Eighty-one patients were included, with a mean follow-up after alemtuzumab of 65 months.

primary endpoint metCONCLUSIONS: In this real-world cohort, alemtuzumab was associated with sustained control of inflammatory disease activity in RRMS, including in patients previously exposed to natalizumab.

relevant ms typesBACKGROUND: The role of alemtuzumab (ALEM) after natalizumab (NTZ) discontinuation in relapsing-remitting multiple sclerosis (RRMS) remains to be better defined in real-world settings.

publication datePublication date: 2026-10-08

follow upRESULTS: Eighty-one patients were included, with a mean follow-up after alemtuzumab of 65 months.

findingsCONCLUSIONS: In this real-world cohort, alemtuzumab was associated with sustained control of inflammatory disease activity in RRMS, including in patients previously exposed to natalizumab.

limitationsTitle: Long-term outcomes of alemtuzumab in relapsing-remitting multiple sclerosis: a real-world cohort with particular focus on treatment sequencing after natalizumab.

AI assessment, not yet reviewed by a person · version 1 · Community votes are separate from evidence review.